Leukemia — Trials · CancerIndex

Clinical trials

Registered studies

8,437 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,769
Recruiting: 1,010
Ph III recruiting: 99
Growth YoY: −2.8%
Industry share: 19%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 35.6%
Trials / 1,000 deaths: 75 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,348)

clinicaltrialsPublishedShowing 201–250 of 539 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03331198	Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)	active not recruiting	Phase 1 / Phase 2	320	Juno Therapeutics, a Subsidiary of CelgeneINDUSTRY	2	Jul 6, 2026	clinicaltrials
NCT05139004	90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome	active not recruiting	Phase 1	7	City of Hope Medical CenterOTHER